A study from Watson School of Biological Sciences shows that Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling. This study was published in the April 10, 2014 Cell by Prof. Dr Scott Lowe, Watson School of Biological Sciences, CSHL, New York; Prof. Dr Carol Prives, Department of Biological Sciences, Columbia University, New York; and others.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Insight into the treatment of Metastatic Pancreatic/intestine/ovarian Cancer: Rhamnetin suppresses the expression of PDGF Receptor β via up regulation of its target gene. Given that tumor suppressor p53 is mutated in about 50% of different human cancers, this study suggests, for the first time, a therapeutic strategy as to how mutant p53 expressing human cancers can be cured.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Insight into the treatment of Metastatic Pancreatic/intestine/ovarian Cancer: Rhamnetin suppresses the expression of PDGF Receptor β via up regulation of its target gene, 6/May/2014, 9.44 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com
* Research cooperation